Abstract. Controversy remains regarding the optimal dose calculation with radioiodine therapy for patients with Graves' disease. Here, we focused our analysis on data concerning the patient's pretreatment background, an empirically set dose of radioiodine and the post-treatment thyroid function, and investigated those factors that affected the outcome. The subjects consisted of 38 patients diagnosed as having Graves' disease. All patients were hospitalized to undertake radioiodine therapy between 1989 and 1998 at our hospital. At the follow-up periods of 6-, 12-, and 36-months after therapy, we divided the patients into two groups: one group those who had hypothyroid function, and the other those who had normal or hyperthyroid function. At 6-and 12-months, 50% of the patients belonged to the hypothyroid function group, whereas at 36-months, 55% of them had hypothyroid function. Logistic regression analysis, with the objective variable being the post-treatment hypothyroidism after 12 months, revealed that the significant factor was the onset age. We suggested that the age at onset should be considered in patients with Graves' disease to determine the optional radioiodine dose for the therapy.
RADIOIODINE therapy is one of the common methods used for the treatment of Graves' disease since 1941 [1, 2] , but there is still no definitive approach to determine the optimum target dose. It is important prevent to recurrence for radioiodine therapy and useful to know predictive factors for treatment outcome.
It has been reported that males [3, 4] , younger patients [5, 6] , patients with more severe hyperthyroidism [5, 6] , patients with goiters of larger size [5] [6] [7] [8] [9] [10] [11] [12] , and patients with high TRAb value [11, 12] were less likely to be cured after radioiodine therapy. Therefore it is possible to reduce the radioiodine dose for the other patients.
There have been few reports concerning the relationship between the predictive factors and outcome of radioiodine therapy in Japan [6, 10, 11] . Similar to European countries, antithyroid medication is first choice for the treatment of Graves' disease in Japan [13, 14] . Radioiodine therapy is chosen only when the patient is resistant to antithyroid medication or it becomes difficult to continue the medication due to various causes such as the development of adverse effects. On the other hand, it has been done as a outpatient treatment in Japan since March 1999 due to revised medical legislation, and therefore the indications for this treatment can be expected to expand.
In this study, we examined the association between pretreatment clinical parameters, an empirically set dose of radioiodine and post-treatment thyroid function to investigate the predictive factors for outcome of radioiodine therapy.
Subjects and Methods

Subjects
Eighty-six patients were hospitalized between 1989 and 1999 for the purpose of radioiodine therapy to treat Graves' disease. Diagnosis of Graves' disease was based on subjective and objective signs of hyperthyroidism, positive TSH-binding inhibiting immunoglobulin (TBII), and 24-h thyroid 123 I uptake. Thyroid 123 I uptake was measured by the uptake at 24 h after oral administration of a capsule containing 7.4 MBq (200 mCi) of 123 I. Family history was taken to the second degree of kinship. Ophthalmopathy was determined by an internist based on clinical symptoms such as exophthalmos, double vision, and impaired visual acuity. Weight of thyroid gland was calculated from thyroid scintigraphy images using the Allen-Goodwin equation [15, 16] : m (g) = 0.323 × S × (a + b)/2 where m = estimated weight of the thyroid gland (g), S = surface area of thyroid gland (cm 2 ) and a, b = length of long axis of left and right lobes (cm), respectively.
The dose of radioiodine (2~10 mCi) was determined empirically based on thyroid size and history of adverse effect to antithyroidal drug by each doctor. The patients were restricted from an iodine-rich diet for 2 weeks before and after the radioiodine administration, and did not take any antithyroid medication during the period.
Assessment of thyroid function after radioiodine therapy
We asked the patients the current frequency of their consultations with general physicians and their medication requirements at 6-, 12-and 36-months after radioiodine therapy. If necessary, we contacted the general physicians with whom the patients had regular consultations and asked the content of their medication or their TSH values. The status of their thyroid functions at 6-, 12-and 36-months after treatment was judged by medical history inquiry by questionnaire or serum TSH levels obtained from blood tests. Among those who undertook radioiodine therapy, 9 male and 29 female patients were eligible for the analyses as described in the results.
We evaluated the thyroid function and classified the patients into the following three groups. Patients who were taking antithyroid medication or whose TSH was lower than normal range were classified as hyperthyroid function. Patients who were not taking antithyroid medication and whose TSH was within normal range were classified as normal. The patients who were taking thyroid hormones or whose TSH was above the normal range without antithyroid medication were classified as hypothyroid function. Hyper-and normal thyroid function groups were combined and the combined group was compared with the hypothyroid function group for analysis.
Statistical analysis
We used unpaired t-test, c 2 tests and, if necessary, performed Yates correction to examine the statistical significance of the parameters before and after radioiodine therapy by comparing the hyper-and normal thyroid function group with the hypothyroid function group. Because the values of weight of thyroid, 24-h 123 I uptake, radioiodine dose (MBq), and dose per weight (MBq/g) did not show a normal distribution, those results were logarithmically transformed before statistical analysis. Logistic regression analysis was performed to identify those factors that affected the treatment result. SAS software version 8.2 (SAS Institute, Cary, NC) was used for all analyses.
Results
Among the 86 patients who undertook radioiodine therapy, the thyroid function of 38 subjects could be evaluated at 6-, 12-and 36-months after the therapy according to the content of medication or their laboratory data. Table 1 shows the patients' backgrounds and the reasons why radioiodine therapy was indicated. In Group I, radioiodine therapy was adapted because of the adverse effects of antithyroid medication. This group consisted of 21 patients (55.3%). Group IV, consisting of those patients in whom radioiodine therapy was the first choice, was comprised of 3 patients (7.9%). Patient's age at onset was the highest in Group I, whereas the duration of the disease was the longest in Group III, which was comprised of those patients who underwent radioiodine therapy after a recurrence. Weight of thyroid gland was the greatest in Group II, which was comprised of those patients who did not effectively respond to antithyroid medication. Radioiodine dose was the highest in Group I. Table 2 shows the values of the various factors in each group categorized by the functional status of the thyroid gland at 6-, 12-or 36-months after radioiodine therapy. The hypothyroid function group represented 50% (19 patients) of the total after 6 months. The proportion did not change at 12-months, but increased to 55% (21 patients) at 36-months. The group of patients with normal thyroid function represented 5% (2 patients), 13% (5 patients) and 16% (6 patients) of the total at 6-, 12-and 36-months after treatment, respectively (data not shown). In contrast, the proportion of patients with a hyperthyroid function decreased from 43% (17 patients) at 6-months to 37% (14 patients) at 12-months and finally to 29% (11 patients) at 36-months (data not shown).
In the hypothyroid function group, both age at onset and age at radioiodine therapy were significantly higher than the normal or hyperthyroid function group at Data are shown mean ± SD. N.S.; not significant 6-, 12-and 36-months after therapy. Duration of the disease was also shorter at 12-and 36-months and the radioiodine dose was higher at 6-, 12-and 36-months. Gender, family history of Graves' disease and presence or absence of ophthalmopathy were not associated with the status of thyroid function after therapy. Although we noticed the trends that TBII values of hypothyroid function group were lower, 24-h 123 I thyroid uptake was lower, weight of thyroid gland was lighter, and radioiodine dose per weight was greater compared with normal or hyperthyroid function group, we could not demonstrate a statistically significant association for these parameter. We conducted a logistic regression analysis with post-treatment reduction of thyroid function as the independent variable, and age at onset, duration of disease, and radioiodine dose as explanatory variables to investigate the predictive factors for outcome of radioiodine therapy (Table 3 ). It was demonstrated that the elderly onset had a statistically significant association with reduced thyroid function after 12 and 36 months. A short duration of disease was also associated significantly with reduced thyroid function after 36 months.
Discussion
Radioiodine therapy in patients with Graves' disease is indicated except for pregnant women and children when antithyroid medication cannot be continued due to its adverse effects [11, 12] . In the case that the thyroid hormone level decreased to normal range after radioiodine therapy, there is the possibility of recurrence or hypothyroidism that may not be realized if the patient does not visit the hospital for follow-up examinations for some years and during follow-up the patients still consider themselves as having poorer health than the general population [17] . Cost-effective analyses recommend ablative treatment [18, 19] . It has been reported that the patients with Graves' disease have a higher rate of thyroid gland cancer as compared with normal individuals or patients with other thyroid gland diseases, although once the thyroid tissues are decreased in size by radioiodine therapy, the frequency of carcinogenesis in fact decreases [18] . Patients who become hypothyroid function have low post-therapeutic thyroid volumes [9, 10, 19] . Therefore, the recommended treatment objective should be to achieve a hypofunctional thyroid within a year, while investigating the factors related to the outcome of thyroid function.
Accordingly, we analyzed the predictive factors correlated to the effect of radioiodine therapy not only to achieve a hypothyroid function but also to prevent the patients from unnecessary exposure to radioiodine in this study. Patients were divided into two groups based on functional state of their thyroid gland: one group of patients whose thyroid gland was hypofunctional after radioiodine therapy, and another group with normal or hyperfunctional thyroid gland. We examined the patients' backgrounds and found that those patients with a higher age at onset seemed to belong to the group with favorable sensitivity to radioiodine therapy. Allahabadia et al. reported the age at onset equal or greater than 40 years old was not a prognostic factor for outcome of radioiodine therapy in 2000 [3] , but they reported it was a prognostic factor in 2001 [4] .
Younger patients had more severe hyperthyroidism at diagnosis and were more likely to fail to respond to medical treatment [20, 21] , therefore their duration of disease might be longer. In the present study, there was a significant negative correlation between age at onset and duration (r = -0.367, P = 0.02, data not shown). The present analysis revealed that the duration of the disease was negatively associated with hypothyroid function at 36 months after radioiodine therapy but not at 12 months (Table 3) . As previously reported, antithyroid medication treatment prior to radioiodine therapy modulates the treatment's undesirable effects [22] [23] [24] . Since patients with long duration of disease might have to take antithyroid medication for long periods of time, this is also one of the reasons why longer duration affects thyroid gland function. It was reported that thyroid glands of greater weight or larger size need more radiation [7] [8] [9] [10] . Some studies have attempted to determine the optimal radioiodine dose based on weight or size of the thyroid gland [6, 9] . However, there were only 2 patients with large thyroid gland over 50 g in our study, hence we did not uncover a significant correlation between the weight of the thyroid gland and the effect of the radiation.
In conclusion, age at onset was a prognostic factor that influenced the thyroid function after radioiodine therapy in the present study. Compared with the patients whose age at onset was higher, the patients with a lower age at onset may need more radioiodine dose to achieve the same clinical outcome. Our study sample was small, so that the other factors including thyroid weight were not entered as statistically significant predictive factors. Further examination is required to investigate what degrees of radioiodine dose are needed for patients with or without certain unfavorable predictive factors, respectively.
